Jason Mast from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Editas Medicine lays off 65% of staff and shelves lead gene-editing program - 8 days ago STAT+: This father built a gene therapy for his son. Now comes the harder part: saving others’ children, too - 12 days ago STAT+: Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases - 24 days ago STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - 29 days ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - about 2 months ago STAT+: Feud between Prime and Tessera, two gene-editing companies, spills out into public - about 2 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 2 months ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 3 months ago STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 3 months ago STAT+: U.K. charities give $36 million to start new drugs for childhood tumors - 4 months ago STAT+: Tome Biosciences files notice to lay off virtually entire staff - 4 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 4 months ago Antiviral used for mpox no better than placebo, NIH says - 4 months ago STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain - 5 months ago STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field - 6 months ago STAT+: Pfizer’s gene therapy for Duchenne muscular dystrophy fails in Phase 3 trial - 6 months ago STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy - 6 months ago STAT+: Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial - 7 months ago STAT+: Gritstone Bio says personalized cancer vaccine falls short in key trial - 9 months ago STAT+: Why the world’s most expensive drug might not be all that overpriced - 9 months ago FDA authorizes new drug to protect immune compromised from Covid-19 - 9 months ago STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives - 9 months ago STAT+: FDA approves first gene therapy for fatal neuron disease in children - 9 months ago STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients? - 9 months ago STAT+: Scientists take a (small) step toward universal antivenom - 10 months ago STAT+: Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - 10 months ago STAT+: For unlucky mountaineers, tundra explorers, and the unhoused, a new drug could avert the ravages of frostbite - 10 months ago STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion - 11 months ago STAT+: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution - 12 months ago STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff - 12 months ago After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes - about 1 year ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - about 1 year ago STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in - about 1 year ago STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill? - about 1 year ago STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion - about 1 year ago ‘Last roll of the dice’ for a near-term HIV vaccine fails - about 1 year ago STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts - about 1 year ago STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children - about 1 year ago STAT+: How sickle cell became the first disease treated by CRISPR - about 1 year ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - about 1 year ago STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial - about 1 year ago STAT+: What to know about Sarepta’s upcoming data on its Duchenne gene therapy - about 1 year ago STAT+: In major test for prime editing, scientists successfully correct mutations in monkeys - about 1 year ago Giant sloths and woolly mammoths: Mining past creatures’ DNA for future antibiotics - about 1 year ago STAT+: Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs - about 1 year ago Zuckerberg and Chan announce a New York biohub to build disease-fighting cellular machines - about 1 year ago STAT+: Peter Marks on creating Operation Warp Speed, but for rare diseases - about 1 year ago STAT+: Sana to lay off nearly a third of staff, de-prioritize a key program - about 1 year ago STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval - about 1 year ago
2	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 3 months ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - about 1 year ago
3	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 4 months ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - about 1 year ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - about 2 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 2 months ago STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial - about 1 year ago
7	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 3 months ago
8	Megan Molteni STAT News	STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives - 9 months ago
9	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - about 1 year ago